Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 study evaluating the safety, pharmacokinetics, and efficacy of alectinib in pediatric participants with ALK fusion–positive solid tumors or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk Fusion-positive Central Nervous System Tumors
• Alk Fusion-positive Solid Tumors

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: ALK Fusion-positive Solid or CNS Tumors | Phase 1, Phase 2 | Status: RECRUITING